

March 13, 2009



Cardiology Snapshot: Hypertension

Event: American College of Cardiology, March 29-31, 2009



Hypertension Market Leaders

Novartis (NYSE:NVS): Diovan, angiotensin II receptor antagonist; 2008 Sales: USD 5.744b

[Novartis' single-pill combinations Diovan HCT and Exforge approved in US as first-line treatments for high blood pressure](#)
[Novartis says a third of 'cluster' of new Tekturna clinical trials is in response to demand for outcome data \(Pharmawire\)](#)
[Novartis/Speedel's hypertension drug Tekturna will likely be used as add-on therapy, physicians say \(Pharmawire\)](#)

Merck (NYSE:MRK): Cozaar, angiotensin II receptor antagonist; 2008 Sales: USD 3.558b

Pfizer (NYSE:PFE): Norvasc, long-acting calcium channel blocker; 2008 Sales: USD 2.211b

*In a recent statement, cardiology was not identified as a high-potential disease area for Pfizer.

[Pfizer appeal on Norvasc patent to Supreme Court rejected, attorney says \(Pharmawire\)](#)
[Pfizer: Supreme Court to make decision in Norvasc case within next six weeks, sources say \(Pharmawire\)](#)

AstraZeneca (NYSE:AZN): Atacand, angiotensin II receptor antagonist; 2008 Sales: USD 1.473b

Bayer (OTC:BAYRY): Rivaroxaban, an orally active direct inhibitor of coagulation Factor Xa; Phase III

[JNJ and Bayer's rivaroxaban may increase bleeding risk in ACS due to layer on top of dual antiplatelet therapy in this setting, physicians say \(Pharmawire\)](#)
[Bayer and J&J's rivaroxaban statistically significant secondary endpoint in the ATLAS study is more clinically relevant than the missed primary endpoint, physicians say \(Pharmawire\)](#)
[Xarelto's ability to compete with Lovenox will be largely determined by cost, clinicians agree \(Pharmawire\)](#)
[Rivaroxaban may receive wider acceptance in EU than the US, doctors speculate \(Pharmawire\)](#)

Astellas (TYO:4503): Micardis, angiotensin II receptor antagonist

[Landmark ONTARGET™ trial demonstrates Micardis® is equally effective as ramipril, with fewer discontinuations, in a broad high-risk cardiovascular population](#)



Unpartnered Targets in Development

Biomarin (NASDAQ:BMRN): Market cap USD 1.06b

Tetrahydrobiopterin - naturally occurring enzyme cofactor required for numerous biochemical and physiologic processes, including the synthesis of nitric oxide (NO)

[Biomarin's 6R-BH4 for peripheral arterial disease likely to be partnered, CEO says; Merck-Serono not interested unless it reaches Phase III trials \(Pharmawire\)](#)

Phase II results expected 1Q09

Arete Therapeutics (Private) USD 51m raised in Series A financing

AR9281 - orally-administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of diabetes and hypertension

[Arete Therapeutics developing soluble epoxide hydrolase inhibitor for diabetes; CEO says company is first to clinic](#)

Phase II results expected early 2010

Ligand Pharmaceuticals (NASDAQ:LGND): Market Cap USD 272m

DARA - a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist

[Pharmacopeia sees accelerated partnership discussions on lead compound for hypertension, may run additional Phase IIb trial, executive says \(Pharmawire\)](#)

[Pharmacopeia receives interest to partner Phase II hypertension compound, will release Phase IIa data next week, SVP says \(Pharmawire\)](#)

Management has expressed an interest in holding talks with prospective partners for the DARA program in 1H09

Cytos Biotechnology (CYTN.SW): Market Cap CHF 118.3m

CYT006-AngQb - a therapeutic vaccine designed to instruct the immune system to produce a specific anti-angiotensin II antibody response

[Cytos CEO details plans for its unpartnered compounds \(Pharmawire\)](#)

Phase II data expected 1H09